Intelligence Platform
Patents
Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 11597774
Antibody variable domains and antibody constructs
granted patentUS 11597707
CGAS antagonist compounds
granted patentUS 11596585
Composition for the prevention of microbial growth
granted patentUS 11596610
Compositions in support of health and mental accuity
granted patentUS 11596671
Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with in
granted patentUS 11596711
Solubilization of antigen components for removal from tissues
granted patentUS 11597765
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
granted patentUS 11596909
System and method for droplet formation and manipulation using ferrofluids
granted patentUS 11597727
Inhibitors of integrin alpha 2 beta 1 and methods of use
granted patentUS 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted patentUS 11596694
Compositions and methods for predicting response to NaPi2b-targeted therapy
granted patentUS 11596696
Combination therapy with an anti-CD25 antibody-drug conjugate
granted patentUS 11596611
Hepatitis B antiviral agents
granted patentUS 11596624
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted patentUS 11596633
SHP2 inhibitor compositions and methods for treating cancer
granted patentUS 11596635
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis
granted patentUS 11596660
Methods of treating bladder cancer
granted patentUS 11596688
Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody
granted patentUS 11596690
Stabilized formulations containing anti-IL-33 antibodies
granted patentUS 11590204
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
granted patentUS 11591613
Retroviral and lentiviral vectors
granted patentUS 11590184
Oncolytic rhabdovirus expressing IL12
granted patentUS 11590179
Bifidobacterium longum able to beneficially modulate immune response to respiratory virus
granted patentUS 11590171
Targeted replacement of endogenous T cell receptors
granted